Ad spend for medical/surgical journals declined by 16.5%, as a combination of patent expiries and regulatory delays stifled 2011’s comeback bid. Marc Iskowitz reports on the numbers for the first half of 2012 by advertisers and brands
Professional journal advertising swung to a loss in the first half of 2012, from an 11.9% gain during the prior-year period. The decline means that print spending has faltered in its attempt to climb beyond recent highs, making a two-year-long rally which MM&M had characterized as one of “restrained recovery” now look more like restraint, plain and simple.
In the first six months of this year, medical/surgical print spending took a 16.5% dive year-on-year, dropping to $168.2 million. On an ad-page basis, the decline was 20.1%. The greater healthcare market (which includes pharmacy, nurse practitioners/physicians assistants, managed care, etc.) registered a 13.9% loss, coming in at $303.1 million, while pharmaceutical spending dropped 20.1% to $169.9 million. For the top 100 most advertised pharmaceuticals, outlays were decreased by a whopping 57% to $57.7 million.
The main reason behind the print market’s softening is one that has become all too familiar: The number of new product launches is not big enough to fill the breach left by expiring drug patents and delayed approvals. There are a few specialty products on the horizon that could inject ad dollars, but no one expects a return to growth this year.
At the journal level, multi-specialty titles were the loss leader. They were down 21.9% year-on-year, representing $14.5 million less in the market. Dollar growth vs. the year-ago period was confined to several niche sectors—healthcare business management, neurology and gastroenterology were the top-performing markets. Twenty-nine of the 37 markets that are tracked by Kantar Media posted losses; among the doctor books, psychiatry, oncology and rheumatology declined most steeply.
Each of the top five medical/surgical journals (ranked by revenue) registered a decrease in ad pages for the first half of 2012. The number-one journal in the field, Monthly Prescribing Reference shed about 269 ad pages, while the number-two Journal of the American Medical Association was down by 377. The New England Journal of Medicine thinned out by 645 ad pages, while American Family Physician was down by 137 pages and Medical Economics plunged 90.
“Everyone was probably hoping for a little better beginning to the year,” acknowledged Mike Guire, director of commercial sales for Elsevier and president, Association of Medical Media (AMM). The decline “seems to be affecting all books in a similar manner, so I don’t think it’s any one thing.”
With many of the traditionally big classes down (multi-specialty, IM and cardiology, for instance), print revenues sank across publishers’ portfolios. Some publishers seem to be weathering the storm better than others—Slack is down by only 5% in revenue, Springer by a relatively small 9%—perhaps helped by their specialty publication focus.
Companies and Products
The extent to which print has suffered can be seen in the company rankings. Forest remained the top print advertiser with a $22.1 million outlay, despite an 8.6% decrease vs. first-half 2011; Johnson & Johnson moved up from fifth to second thanks to a $527,000 increase; and Pfizer hovered in third place, notwithstanding a 25.4% budget cut.
Only two companies broke into the top 10 this year—GlaxoSmithKline and Purdue. Their 96.8% and 48.4% increases, respectively, knocked out Sanofi and Merck. The other six of 2012’s first-half top 10 (Pfizer, Novo Nordisk, Novartis, Takeda, Lilly and Roche) severely curtailed print spend yet remained in the upper decile.
The top 25 products accounted for 20% of all spend in the market, with $61.5 million (down by more than half vs. the first six months of last year). Forest has the top-advertised drug, antidepressant Viibryd, and four of the 10 most-advertised brands. Viibryd, up from number 11 last year thanks to a 173% push, and one other Forest drug enjoyed spending hikes, vs. a dial-back on fibromyalgia med Savella and BP product Bystolic. Among the top 25 brands were seven newly advertised products, adding $18.2 million into the market.
J&J hiked spend 6% to $8.9 million behind launches for prostate cancer drug Zytiga and blood thinner Xarelto. Those launches also helped propel the Antineoplastic Agents and Anticoagulants Oral classes to first and third place, respectively, on the list of most-advertised categories in the six months to June. Rounding out the top five classes by sales, the SSRI/SNRI and Diabetes Insulin classes—highly ranked the last several years—were also joined by Beta Agonists Oral, up from 35th place during first-half 2011.
“There were 482 brands that did journal advertising in first half of 2011, versus 480 brands in the same period in 2012,” observes Kelly Sborlini, VP of syndicated market research operations at Encuity Research. “However, the average spend per brand in the first half of the year decreased by about $40,000 from $324,000 in 2011 to $281,000 in 2012,” her firm’s data show.
There does seem to be a silver lining for journal publishers, and it’s the growth of digital advertising. As digital spend is not captured in the conventional tracking services, MM&M asked whether online advertising is up and how else revenue sources are diversifying.
Consensus among a number of AMM members, according to Guire, is that they are experiencing revenue gains in newer media channels like on-site advertising, microsites and e-blasts, licensing, events and digital broadcasts. Another growth area has been ads on iPad apps. Wolters Kluwer says its Lippincott Williams and Wilkins (LWW) titles have mitigated print losses, and boosted digital revenues, after the publisher stopped offering advertisers the option of print-only ads. Print and digital apps are sold together at one price.
First-half print revenue for the LWW journals declined by 10.8% vs. the year-ago period. By contrast, Elsevier revenues fell 18%, Advanstar 17% and the American Medical Association 25%. “When we look at revenue at the macro level,” says Karen Abramson, president and CEO of Wolters Kluwer Health Medical Research, “we’re outperforming the market and we attribute this lift in part to the bundled ad model we introduced in January.”
Meanwhile, Kantar’s Evaliant data show brand managers may be getting smarter about using multiple platforms to reach their audiences. Nine of the top 10 print advertisers (based on number of insertions) also show up in the top 30 companies online (based on occurrences), with most falling in the top 20. Forest, the biggest print advertiser, ranked 11th in online occurrences. That’s a big improvement over last year at this time, when the drugmaker had no presence on the major websites tracked by Evaliant (Forest could have been engaging in other types of online promotion, such as e-detailing, e-sampling or microsites). Four firms were in the top 10 both in print and online: Pfizer, J&J, Novartis and Roche, vs. two last year.
At the brand level, several top online brands (based on occurrences) aren’t in the top 100 print brands (based on insertions), and vice versa. Only Daliresp (number six online, two in print) and Xarelto (number eight online, three in print) hit the top 10 in both media. Many of the most widely advertised brands (those using the most sites) were, not surprisingly, also among the top in occurrences.
In this era when more clinicians use portable devices to consume professional journal content, and pharma advertisers are allocating promotional spend between many channels, it might be unrealistic to think journal ad spend will move any direction but sideways. On the other hand, IMS Health’s Global Use of Medicines Outlook report predicts that drug approvals—the main driver of promotion—will improve and that pharma will launch 30-something NMEs each year through 2016. Will that help print stage a sustained comeback?
Says Wolters Kluwer’s Abramson, any return to R&D productivity must be viewed against the backdrop of shrinking pipelines for blockbuster products and pharma’s shift to deliver more niche drugs. “When you define print journal pages as advertising, then yes, we’ll continue to see a decline and fluctuations,” she predicts. “But today, we need to look at this industry in a positive transformation that’s defined by the audience reach across multiple channels.